[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574393":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":45,"id":49,"slug":18,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":18,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":18,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":27,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Teniposide group","Teniposide administration",[12],"Drug: Teniposide administration",[14],{"type":15,"name":10,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Teniposide administration: 60mg\u002Fm2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 3-5 consecutive days, with 21 days as one cycle of treatment.",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"jiale Wang","CONTACT","+86 21 65115006","wangjiale200008@163.com",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Shanghai","Shanghai Municipality","200331","China",{"type":33,"coordinates":34},"Point",[35,36],121.45806,31.22222,{"lat":36,"lon":35},[39],{"name":40,"role":22,"phone":23,"phoneExt":18,"email":24},"Jiale Wang",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Ren Shengxiang","Prof.",[46],{"name":47,"class":48},"CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD","UNKNOWN","100574393",false,"NCT06758700","Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer","Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n1. extensive stage small cell lung cancer\n2. Progression after receiving at least one chemotherapy drug treatment in the past;\n3. ECOG score 0-1\n4. c-Myc-driven\n5. Expected survival period ≥3 months\n6. Age: 18-75 years old;\n7. The informed consent form complies with the ICH-GCP principles.\n\nExclusion Criteria:\n\n1. No measurable lesions\n2. Other severe and persistent diseases or organ system dysfunction;\n3. Women planning pregnancy or men planning family planning;\n4. Women who are pregnant or breastfeeding;\n5. Those who cannot follow the research protocol provided by the investigator.","ALL","18 Years","75 Years",{"count":59,"type":60},15,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2\u002FMYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2\u002FMYC and the efficacy of teniposide.",[66,67,68,69],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","Thoracic Neoplasms","Lung Neoplasms","Lung Diseases",[71,72,73,74],"c-Myc","SCLC","Phase II","Post-line","2025-11-30",{"date":77,"type":78},"2025-12-05","ACTUAL",{"date":80,"type":78},"2025-02-07",{"date":82,"type":60},"2026-12-31",{"name":5,"class":6},1]